Full-Life
Technologies seals $571.5
million agreement with SK
Biopharmaceuticals to license and further develop Full-Life's
'FL-091' radiopharmaceutical compound into an innovative
anti-cancer treatment for worldwide markets
HEIDELBERG, Germany and
SEOUL, South Korea, July 16, 2024 /PRNewswire/ -- Full-Life
Technologies ("Full-Life"), a fully integrated global
radiotherapeutics company, announced today that it has entered into
a license agreement with SK Biopharmaceuticals, a global biotech
company, for exclusive worldwide clinical research,
development, manufacturing, and commercialization rights to
Full-Life's "FL-091" radiopharmaceutical compound targeting
neurotensin receptor 1 (NTSR1) positive cancers.
This licensing deal worth $571.5
million includes an upfront payment, and development and
commercial milestones, separate from royalties. Under the terms of
the agreement, SK Biopharmaceuticals will in-license the
NTSR1-targeting Radionuclide Drug Conjugate (RDC) program FL-091 –
as well as its back-up compounds – aimed at developing and
commercializing it as an innovative anti-cancer drug.
FL-091 is a small-molecule radioligand vector designed to
deliver targeted radiation therapy to cancer cells by binding
specifically to NTSR1, a receptor protein, which is selectively
overexpressed in various types of solid tumors, including
colorectal cancer, prostate cancer, and pancreatic cancer.
SK Biopharmaceuticals also has a right of first negotiation to
license other pre-selected RDC programs of Full-Life.
Lanny Sun, Chief Executive
Officer of Full-Life, said, "This agreement with SK
Biopharmaceuticals highlights the potential of FL-091 in advancing
cancer treatment and demonstrates SK Biopharmaceuticals' unwavering
commitment to building an oncology business around medical
innovation. We look forward to future collaborations with SK
Biopharmaceuticals, and to leveraging its expertise and resources
to advance radiopharmaceutical therapy. The agreement is aligned
with our strategic vision of fostering global partnerships and
making a meaningful impact on patients worldwide."
Donghoon Lee, Chief Executive
Officer and President of SK Biopharmaceuticals, said, "The
licensing agreement with Full-Life not only brings the two
companies closer together for future collaborations in the fastest
rising biotech sector, but also most importantly, pushes SK
Biopharmaceuticals forward to become a 'Big Biotech'. Since the introduction of the company's
strategy roadmap to venture into radiopharmaceuticals last year, we
have been on track toward our envisioned goal. We expect to further
unveil and implement business plans for RPT (radiopharmaceutical
therapy) this year, and actively pursue clinical development and
commercialization in the near future to provide treatment options
and create new value worldwide."
About FL-091
FL-091 is a novel small-molecule radioligand vector targeting
NTSR1 positive solid tumors. Overexpression of NTSR1 has been
associated with disease progression of multiple types of cancers,
including colorectal, breast, pancreatic, and head and neck
cancers. FL-091 radioligands have demonstrated favorable
biodistribution profiles and enhanced binding affinity to NTSR1, as
well as encouraging anti-tumor activities in preclinical studies.
The development of the alpha-emitter therapy candidate
225Ac-FL-091 targeting NTSR1-positive tumors is
currently in progress.
About Full-Life Technologies
Full-Life Technologies ("Full-Life") is a fully integrated
global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain
for radiopharmaceutical research & development, production
& commercialization to deliver clinical impact for patients.
The Company endeavors to tackle fundamental challenges affecting
radiopharmaceuticals today by pioneering innovative research that
will shape the treatments of tomorrow. We are comprised of a team
of fast-moving entrepreneurs and seasoned scientists with a proven
history of success in the life sciences, alongside radioisotope
research and clinical development. For more information, visit
Full-Life's website at www.full-life.com.
About SK Biopharmaceuticals
SK Biopharmaceuticals focuses on the research, development and
commercialization of treatments for disorders of the central
nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals
established a research center to begin its expansion into oncology
through research and development efforts.
SK Biopharmaceuticals is the first and only Korean company to
independently develop and commercialize an antiseizure medication,
cenobamate (brand name: XCOPRI®) in the U.S. More than 100,000
patients have been treated globally with cenobamate, developed by
SK Biopharmaceuticals and its U.S. subsidiary SK Life Science,
Inc., since its launch in the U.S. in 2020. Cenobamate has
successfully entered five major regions: North America, Europe, Asia,
Central and South America, and the
Middle East and North Africa.
The company also has a pipeline of eight compounds in
development in both CNS disorders and oncology. Additionally, SK
Biopharmaceuticals is focused on the discovery of new treatments in
oncology. For more information, visit SK Biopharmaceuticals'
website at www.SKBP.com/eng, and SK Life Science's website at
www.SKLifeScienceInc.com.
View original
content:https://www.prnewswire.com/news-releases/full-life-technologies-sk-biopharmaceuticals-enter-licensing-agreement-for-novel-therapeutic-targeting-multiple-solid-tumors-302197884.html
SOURCE Full-Life Technologies